Phaseline

Companies › Smart Immune SAS

Smart Immune SAS: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
SMART101
Allogeneic T cell progenitors to accelerate immune reconstitution
–Phase 1Hematological MalignanciesMay 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04959903SMART101Phase 1Hematological MalignanciesOncologyMay 2027

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

No annotated target.

Companies with the same targets

–

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.